The Potential Link Between Eosinophilic Esophagitis and Food Allergy: Inflammatory Pathogenesis and Management Authors: Maria Parmigiani, Irene Maria Rita Giuliani, Elena Grueso-Navarro, Alfredo J Lucendo Published: 2026 ABSTRACT AbstractEosinophilic esophagitis (EoE) has transitioned from an isolated gastrointestinal disorder to a recognized type 2 immune-mediated allergic disease, most likely representing a late manifestation of the atopic march. This comprehensive review examines the complex inflammatory pathogenesis linking EoE and food allergy, and critically discusses the mechanisms of disease induction, dietary treatments, and emerging clinical challenges. While genome-wide association studies identify shared susceptibility loci with classic atopy, EoE exhibits distinct tissue-specific pathways, particularly dominated by the local interleukin (IL)-13 axis and highly esophagus-selective proteases like Calpain-14. This unique immunological interplay is clinically epitomized by food oral immunotherapy (OIT)-induced EoE. During OIT, systemic immune reprogramming successfully drives immune tolerance—marked by a robust increase in plasma food-specific IgG4—but fails at the local level, due to the persistence of pathogenic Th2 cells and aberrant mucosal IgG4 immune complex deposition within the esophageal lamina propria. Regarding therapeutic management, conventional skin and serum allergy testing remain highly inaccurate in identifying dietary triggers, rendering test-guided diets ineffective. Conversely, empiric elimination diets achieve robust histological remission, ranging from standardized six-food restrictions to pragmatic single-food approaches targeting cow’s milk. Furthermore, novel insights into industrial milk processing (such as UHT sterilization and homogenization) and specific beta-casein genetic variants (A1 vs A2) highlight how altered protein structures generate neoantigens that accelerate esophageal immunogenicity. In conclusion, decoding the divergent immunological mechanisms operating in the refractory esophagus is essential to move beyond trial-and-error dietary interventions towards non-invasive monitoring tools, precision medicine, and optimized biological therapies in EoE management.Keywords: eosinophilic esophagitis, immunotherapy, oral, diet, food hypersensitivity, immunoglobulin G4, Calpain14, food handling Introduction Eosinophilic esophagitis (EoE) is a chronic, immune-mediated disease of the esophagus that affects patients of all ages. Clinically characterized by symptoms of esophageal dysfunction, its age-dependent manifestations often overlap; while dysphagia and food impaction dominate in adults, heartburn, chest pain, and vomiting are the most characteristic features in children.1 EoE is histologically defined by a prominent eosinophil-predominant inflammation restricted to the esophagus.2,3 With the first cases described in the literature in the 1980’s,4 EoE was characterized as a distinct clinico-pathological disorder in 1993.5 Once considered a rare condition, its incidence and prevalence have risen significantly worldwide over the past few decades6 to affect today at least 1 out of 600 people in the USA and Europe.7,8 While initially viewed as an isolated gastrointestinal disorder, a frequent association with atopic conditions was identified from early cases.9 Most of these patients presented a personal and/or family history of asthma, rhinitis, conjunctivitis, eczema,10,11 and IgE-mediated food allergies, along with blood eosinophilia and food and environmental sensitizations, identified through positive results in serum and skin allergy tests.12 With this growing body of evidence highlighting a deep connection between EoE and atopic conditions,13 the concept of EoE has shifted currently towards that of a type 2 allergic disease, and proposed as a late manifestation of the atopic march.14 Food allergens play a critical role in driving the pathogenesis of EoE, acting as primary triggers for the chronic inflammation and subsequent tissue remodeling observed in the esophagus. This led to EoE being considered a particular form of food allergy, effectively managed with dietary therapy.15 This close relationship is further emphasized by the emerging risk of developing EoE during food oral immunotherapy (OIT),16 a phenomenon that highlights the complex immunological interplay between regular food tolerance and esophageal hypersensitivity.17 Understanding this dual nature of EoE is essential for optimizing patient care. This review aims to examine the shared inflammatory pathogenesis between EoE and food allergy, to discuss the clinical challenges of OIT-induced EoE, and to evaluate the current landscape and efficacy of dietary interventions. Pathophysiology of EoE: The Role of Type 2 Allergy Epidemiological Associations of EoE and Atopic Diseases The link between EoE and atopy has been formally quantified in two systematic reviews with meta-analyses, which together provide the strongest pooled evidence to date. González-Cervera et al synthesized 21 observational studies comprising more than 53,000 patients with EoE and a comparable number of controls. They demonstrated that, compared with the general population, patients with EoE had increased odds of allergic rhinitis (OR 5.09; 95% CI 2.91–8.90), asthma (OR 3.01; 95% CI 1.96–4.62), and atopic dermatitis (OR 2.85; 95% CI 1.87–4.34). However, these estimates were limited by heterogeneity, potential publication bias for asthma, and variable definitions of atopy.10 Nearly a decade later, Ji et al revisited this association using a more restrictive approach—including only studies with clinically and histologically confirmed EoE—to evaluate over 1800 cases and 3000 controls across 27 studies.13 This analysis reinforced previous findings, showing that more than half of the patients with EoE presented with at least one atopic comorbidity (OR 3.56; 95% CI 2.27–5.59). Significant associations were observed for allergic rhinitis, atopic dermatitis, asthma, and food allergy, with the latter notably showing no between-study heterogeneity. An observational study by Guarneri et al approached this question from a different perspective by describing the coexistence of EoE within a cohort of 6000 food-allergic patients enrolled in the FARE registry.18 Their findings demonstrated that, within a food-allergic population, the odds of developing EoE increase, along with multiple atopic comorbidities and the cumulative number of reported food allergies. Nevertheless, because the study relied on self-reported conditions rather than histologically confirmed diagnoses, its conclusions should be treated with caution. While these epidemiological data establish a clear co-occurrence that points toward a closely shared etiology, the genetic architecture of EoE also reveals a significant mechanistic overlap with classic atopic manifestations, reinforcing its classification within the allergic spectrum. Genome-wide association studies have identified several susceptibility loci (including 2p23, 5q22, and 11q13) and key candidate risk genes—such as thymic stromal lymphopoietin (TSLP), Calpain-14 (CAPN14), GATA binding protein 3 (GATA3), and EMSY—that link EoE to conditions like allergic asthma and atopic dermatitis.19,20 This genetic predisposition orchestrates a pathogenic triad involving barrier dysfunction, endogenous protease dysregulation, and Th2-mediated immune activation.21 Specifically, variations in TSLP promote the recruitment of allergic effector cells and the secretion of soluble Th2 mediators, including interleukin (IL)-4, IL-5, and IL-13. Concurrently, the upregulation of the highly esophagus-selective protease CAPN14, alongside the downregulation of filaggrin and serine peptidase inhibitor Kazal type 7 (SPINK7), induces severe epithelial barrier defects and heightened proteolytic activity.21,22 This interconnected genetic and immunological cascade mirrors the epithelial-mesenchymal dysfunction observed in classic airway and cutaneous atopies, highlighting a shared underlying etiology.23–26 However, a recent study revealed only a partial genetic overlap between EoE and individual atopic diseases, indicating that while EoE shares certain allergic features, its genetic correlation is comparatively weak compared to classic allergic disorders.27 This apparent duality is closely reflected in the immunological cascade underlying EoE. The Role of Allergens in Triggering Esophageal Damage The transition of the esophageal mucosa to a highly inflamed, remodeled state hinges on chronic exposure to specific luminal antigens, where allergic sensitization likely drives sustained type 2 inflammatory signaling.28,29 This process involves a complex, delayed immune response, potentially incorporating both non-IgE mechanisms and a late-phase IgE-mediated response similar to chronic inflammation in asthma or allergic rhinitis, rather than just acute reactions.29 This late-phase reaction is characterized by sustained inflammatory signaling, tissue remodeling, and significant eosinophil infiltration into the mucosal tissue, which can progress without presenting immediate systemic symptoms. Dietary proteins—chiefly from cow’s milk, wheat, hen’s egg, and soy or legumes—serve as the predominant triggers.30 For these macromolecules to initiate downstream adaptive cascades, they must first pass through the protective mucus layer,31 and then cross the stratified squamous epithelium. In genetically predisposed hosts, epithelial barrier vulnerabilities—such as desmosomal and tight junction impairment—facilitate this translocation. However, the initial inflammatory mechanisms driving this barrier dysfunction are not yet defined.32 Additionally, specific food proteins exhibit intrinsic enzymatic activity capable of directly cleaving junctional complexes, thereby accelerating mucosal permeability and perpetuating chronic inflammation.33 Furthermore, seasonal aeroallergens (eg pollens) can be swallowed or cross-react with food proteins via molecular mimicry, likely provoking seasonal clinical exacerbations and compounding the local antigenic load.34 Shared and Divergent Type 2 Immune Mechanisms in EoE Upon the exposure to luminal allergens, the allergic inflammation induces epithelial stress, barrier disruption and translates mostly into the release of alarmins (TSLP, IL-33, and IL-25). Alarmins mediate the activation of dendritic cells (DCs) and innate type 2 immune cells (innate lymphoid cells (ILC)-2, mast cells and basophils).35,36 Locally in the esophagus, alarmin-stimulated ILC-2 and mast cells contribute to the impaired esophageal epithelial barrier via the increased production of amphiregulin,37 and oncostatin M,38 respectively. Then, DCs process the allergen and present the antigenic peptides to naïve CD4+ T—cells inducing their polarization into T helper 2 (Th2) cells. Once established, the Th2 response is amplified through the inflammatory cytokines IL-4, IL-13, IL-5 and IL-9, each of which is specialized in different aspects of the Th2 immunomodulatory response. IL-4 is essential for the B-cell class switch; IL-5 promotes eosinophil maturation and tissue-recruitment; IL-9 contributes to the expansion of mast-cells; and IL-13 affects epithelial and stromal cells, promoting barrier dysfunction and tissue remodeling (Figure 1).39 Pathophysiological sequence of Eosinophilic Esophagitis. In the canonical IgE-mediated allergy, the allergen-specific B cells differentiate into IgE-producing plasma cells that, upon re-exposure to the allergen, induce the release of histamine, lipid mediators and cytokines by degranulation of mast cells and basophils.35,40 EoE however, shows an alternative pathway independent of IgE, as evinced by the fact that treatment with omalizumab – an anti-IgE therapy – did not improve symptoms or tissue eosinophilia in the majority of adults with EoE,41,42 and the limited ability of conventional allergy testing to identify EoE triggers through IgE.43,44 Consistently, EoE appears to be dominated by the IL-13 axis and not IL-4,45 based on its overexpression in EoE biopsies and reproduction of an EoE transcriptomic signature induced by IL-3 stimulation.39,46 What remains unresolved is why the recognition of mostly food-antigens evolves towards a chronic tissue-specific type 2 inflammation, rather than the canonical IgE-mediated hypersensitivity. Alternatively, IgG4 emerged as a feature of EoE when an increase of food-specific IgG4 responses and abundant IgG4-positive plasma cells and deposits in esophageal tissue were reported in adults with EoE.42,47 Although the biological function of IgG4 in EoE remains unresolved, it is postulated; because of its noninflammatory properties, deficiency of IgG4 could be linked to the development of EoE.48,49 EoE and the Atopic March The concept of an “allergic” or “atopic march” emerged from epidemiological and longitudinal observations suggesting that allergic diseases tend to appear in an ordered sequence during childhood.50 Early studies suggested that familial history of atopy and greater severity of early atopic disease increase the risk of developing subsequent allergic manifestations.51 Classically, this sequence begins with atopic dermatitis and IgE-mediated food allergy, followed later by asthma and allergic rhinitis. Supporting this age-dependent pattern, an early meta-analysis that analyzed the age of onset of atopies reported that atopic dermatitis and food-allergy frequently started during the first year of life; whereas respiratory allergies showed a later and broader onset, with most asthma cases appearing by 8 years of age and allergic rhinitis more commonly emerging after infancy.52 However, although the classical model remains useful, it is no longer considered a universal or linear pathway.53 In a more recent longitudinal study, the minority of children resembled the classical atopic march,54 indicating the power of genetic and environmental factors driving multiple allergic trajectories. Hill et al first proposed EoE as a late manifestation of the atopic march. In a virtual birth cohort of more than 130,000 children, pre-existing IgE-mediated food allergy was associated with a nine-fold increased risk of subsequent EoE, while weaker but significant associations were also observed for pre-existing atopic dermatitis, allergic rhinitis, and asthma.14 A recent retrospective study of more than 500,000 US children reported similar findings, showing an increased risk of EoE in patients with pre-existing atopic diseases, stronger for food allergy and asthma.55 Together, these independent and cumulative associations suggest that EoE may represent a late outcome within broader allergic disease trajectories. However, prospective longitudinal studies specifically addressing this temporal relationship still remain limited and conclusions should be made cautiously. Food Oral Immunotherapy and Risk of Eosinophilic Esophagitis OIT has emerged as a proactive treatment to induce desensitization in both pediatric and adult patients with IgE-mediated food allergies. It involves the oral administration of increasing amounts of a food allergen to achieve desensitization.56 Therefore, the primary goal of this technique is to raise the reaction threshold to trace amounts of the culprit food while the patient undergoes OIT.57 A potential secondary goal is sustained unresponsiveness, even after discontinuing therapy58,59—typically after years of OIT—although this outcome is not achieved in all patients (30–74% for peanut OIT, 33–50% for milk OIT, and up to 71% for egg OIT).56,57 Diverse OIT protocols have been established over time. The selection of an OIT protocol dictates a clear clinical and immunological bifurcation: Low-dose regimens target transient desensitization by gradually desensitizing mast cells and basophils to IgE—suppressing degranulation without altering the underlying Th2-driven adaptive response.60,61 Conversely, high-dose protocols aggressively pursue sustained unresponsiveness. This deeper therapeutic shift relies on T-regulatory (T-reg) cell induction and an antibody class switch from IgE toward protective IgG and IgA production.62 While high-dose maintenance successfully promotes higher rates of sustained unresponsiveness, achieving complete ad libitum consumption remains a minority outcome.58,60 This translational gap is further compounded by a critical clinical hurdle: except for standardized peanut preparations approved in Europe and North America, the OIT landscape for other major allergens lacks commercially standardized formulations.63 Consequently, the reliance on heterogeneous, non-standardized products introduces variable protein dosing, elevating the risk of severe systemic reactions and therefore mandating strict, patient-specific medical supervision.64 Safety Concerns in Food OIT: The Risk of EoE The widespread clinical adoption of OIT has revealed significant safety concerns. Adverse events consist of allergic reactions, manifested as itching or tingling in the mouth and throat, hives or rashes, and a runny nose or sneezing. Regarding the gastrointestinal reactions to OIT, immediate abdominal discomfort, and nausea and vomiting, with peripheral eosinophilia >600/µL, may appear in around 20% of patients.60 However, these subside within a short time in most sufferers.65 Most notably the de novo development of EoE represents the most direct, observable link between immediate IgE-mediated hypersensitivity and delayed, non-IgE-mediated esophageal inflammation.66 Following the definitive clinical criteria established by the EAACI Working Group, OIT-induced EoE is defined in this article as a combination of symptoms of esophageal dysfunction that appear after the onset of dietary OIT along with the demonstration of a peak eosinophil count of ≥15 eos/hpf in esophageal mucosal biopsies.67 The exact incidence of OIT-induced EoE remains a subject of ongoing debate, largely due to differences in screening protocols, detection bias, and patient dropout rates across clinical studies. Many patients who experience persistent gastrointestinal adverse events during OIT simply discontinue the therapy, without ever undergoing an upper endoscopy to confirm a diagnosis, thus disguising the true burden of this complication. Even so, systematic reviews and meta-analyses estimate that the overall prevalence of confirmed EoE after food OIT ranges between 1.8%16 and 2.7%,67,68 with no differences demonstrated across age groups. In contrast, a recent retrospective study involving 1200 children undergoing OIT found that 51 underwent evaluation for suspected EoE, and only 8 (0.7%) were ultimately diagnosed with EoE,69 which is lower than prior studies. This complication has been documented across various food allergens, including cow’s milk, hen’s egg, and peanut OIT. A comparison of peanut vs egg vs wheat showed similar results, with an incidence of EoE ranging from 1.68% to 2.27%, with overlapping confidence intervals. In contrast, the incidence of EoE was 4.36% after milk or egg immunotherapy.67 No significant difference in EoE incidence was found across studies including patients receiving immunotherapy for one food or more than one food.67,69 It is important to mention that a prospective study performing baseline endoscopies before OIT has revealed that up to 14% of asymptomatic food-allergic adult candidates already had subclinical esophageal eosinophilia (≥15 eos/hpf) prior to starting OIT.70 This proportion increased up to 33% in a recent pediatric series,71 complicating the distinction between true de novo induction and the revealing of pre-existing pre-clinical disease. Pathophysiological Mechanisms The development of EoE during OIT provides a unique model for understanding the pathogenesis of eosinophilic gastrointestinal diseases. While OIT successfully suppresses acute, IgE-mediated mast cell and basophil activation by reprogramming the immune system for tolerance, the esophagus emerges as a refractory organ in which food antigen exposure can simultaneously drive a delayed type 2 helper T (Th2) cell response.62,72 During successful OIT, constant allergen exposure induces an isotype switch in systemic B lymphocytes, resulting in a marked decrease in specific IgE and a robust increase in specific Immunoglobulin G4 (IgG4).73,74 Clinically, IgG4 acts as a blocking antibody that competes for the allergen, preventing systemic degranulation of mast cells and basophils and mitigating the risk of anaphylaxis.75 However, in the patients who develop EoE after OIT, this tolerance mechanism appears to fail or is insufficient at the local level due to two critical factors: a)Persistence of pathogenic type 2 helper T lymphocytes (peTh2):76 OIT manages to suppress immediate antibody (IgE)-mediated reactivity, but frequently fails to eradicate or abolish early food-specific Th2 T cell clones. These peTh2 cells continue to migrate towards the esophageal mucosa, stimulated by repeated swallowing of high doses of antigen.77 Persistence of pathogenic type 2 helper T lymphocytes (peTh2):76 OIT manages to suppress immediate antibody (IgE)-mediated reactivity, but frequently fails to eradicate or abolish early food-specific Th2 T cell clones. These peTh2 cells continue to migrate towards the esophageal mucosa, stimulated by repeated swallowing of high doses of antigen.77 b)The tissue IgG4 paradox: Although plasma IgG4 prevents anaphylaxis,78 a dual phenomenon occurs in the esophageal microenvironment.47 Histological studies reveal massive deposits of IgG4 in the mucosa of patients with EoE.42,79 Rather than acting as a local tolerogenic factor, it is postulated that the dense accumulation of IgG4 forms immune complexes in situ80 that could bind to Fcγ receptors of local antigen-presenting cells,81 inadvertently amplifying antigenic uptake and proinflammatory Th2 signaling.82 The tissue IgG4 paradox: Although plasma IgG4 prevents anaphylaxis,78 a dual phenomenon occurs in the esophageal microenvironment.47 Histological studies reveal massive deposits of IgG4 in the mucosa of patients with EoE.42,79 Rather than acting as a local tolerogenic factor, it is postulated that the dense accumulation of IgG4 forms immune complexes in situ80 that could bind to Fcγ receptors of local antigen-presenting cells,81 inadvertently amplifying antigenic uptake and proinflammatory Th2 signaling.82 An unresolved question is whether OIT truly induces de novo EoE or instead unmasks a previously asymptomatic disease. Baseline endoscopic and histological studies demonstrating that some asymptomatic candidates exhibit esophageal eosinophilia prior to initiating OIT strongly suggest that both mechanisms likely contribute to the clinical presentation of the disease. However, because routine baseline endoscopies are rarely performed in standard clinical desensitization protocols, differentiating between a newly triggered immune response and the exacerbation of a latent, subclinical condition remains an active area of investigation. Clinical Identification and Management Distinguishing temporary, mild gastrointestinal side effects from true OIT-induced EoE is a major clinical challenge. While early OIT-related symptoms —such as transient abdominal pain or nausea— often resolve during the maintenance phase, EoE-related symptoms are typically persistent, and include progressive dysphagia, vomiting, abdominal pain or food impaction.83 EoE can develop at any point in therapy, but two time points have been described for developing EoE-like symptoms during OIT. Most seem to appear early in the course of treatment, often manifesting as vomiting and/or abdominal pain.84 However, there are also reports of symptoms developing 2 to 3 years after starting OIT.85,86 Currently, there are no evidence-based recommendations for the management of gastrointestinal adverse events during OIT.87 Initial strategies, according to the OUtMATCH consortium guidelines,83 prioritize stepwise pharmacological optimization—through the sequential use of H1/H2 antihistamines (preferable over the use of proton pump inhibitors [PPIs], so as not to mask a PPI-responsive EoE), proton pump inhibitors (PPIs), and temporary OIT dose reduction—in order to avoid premature discontinuation of allergy treatment (Figure 2). However, from a strictly critical perspective, this “symptomatic masking” approach carries a risk of delaying the definitive diagnosis of EoE. When OIT-induced EoE is confirmed via biopsy, management strategies may present a complex clinical challenge,88 requiring a delicate balance between systemic allergy desensitization and local esophageal histological integrity. While complete discontinuation of OIT supports EoE remission,89,90 most authors currently advocate for a personalized, combined approach that attempts to maintain OIT. This strategy is primarily driven by the clinical need to preserve the desensitization state, as full cessation of immunotherapy exposes the patient once again to a severe risk of systemic anaphylaxis upon accidental allergen ingestion. Recent data indicate that OIT-induced EoE can be successfully managed through a shared decision-making model by co-administering first-line drugs—such as proton pump inhibitors (PPIs) or swallowed topical corticosteroids—or via OIT maintenance dose adjustments, which mitigate esophageal symptoms and inflammation, while prevent loss of tolerance.84,91,92 Standard anti-inflammatory therapies appear to be equally effective in OIT-induced EoE,93 but the cessation of OIT must remain a therapeutic option considered by both physicians and patients when pharmacological treatment fails.91 Comparative features regarding clinical, epidemiological, and management strategies of sporadic versus OIT-induced EoE are outlined in Table 1. Proposed clinical algorithm for the management of upper gastrointestinal symptoms and eosinophilic esophagitis during oral immunotherapy. Table 1Comparative Features Between Sporadic and Oral Immunotherapy-Induced Eosinophilic EsophagitisFeatureSporadic Eosinophilic Esophagitis (EoE)Oral Immunotherapy-Induced EoE (OIT-EoE)Primary TriggerChronic, delayed non-IgE-mediated exposure to multiple dietary proteins (eg, cow’s milk, wheat, egg)Direct administration of escalating high doses of a specific target food allergenOnset DynamicProgresses independently, often as a late stage or trajectory of the classical atopic marchDevelops de novo or unmasks subclinical baseline disease during active targeted desensitization therapyTime to Symptom PresentationTypically manifests gradually over several years, leading to diagnostic delaysFrequently presents early during the initial build-up phase, or alternatively 2 to 3 years into maintenanceCommon Clinical PresentationAdults: Solid food dysphagia and food impaction. Children: Heartburn, chest pain, and vomitingPersistent gastrointestinal side effects, prominently characterized by early-onset vomiting and abdominal painEstimated Prevalence/IncidenceAffects at least 1 out of 600 individuals across the United States and EuropeOverall meta-analytic prevalence ranges between 1.8% and 2.7% among patients undergoing food OITDiagnostic ChallengesRequires invasive, repeated upper endoscopies due to a current lack of validated non-invasive biomarkersDistinguishing transient, self-limiting OIT side effects from true chronic esophageal tissue inflammation without biopsyFirst-Line Management StrategiesEmpiric food elimination diets, PPIs, or topical corticosteroidsStepwise pharmacological optimization (PPIs, corticosteroids), temporary OIT dose reduction, or complete OIT discontinuationImpact of Stopping Trigger ExposureDietary restriction leads to tissue remission, but symptoms recur rapidly upon standard food reintroductionDiscontinuing the culprit oral immunotherapy protocol reliably guarantees complete histological and clinical EoE remission Comparative Features Between Sporadic and Oral Immunotherapy-Induced Eosinophilic Esophagitis The Evolving Landscape of Dietary Treatment for EoE Dietary therapy is at the forefront of managing EoE:2 unlike pharmacological approaches, it targets the underlying antigenic trigger rather than suppressing downstream inflammation, and can achieve true disease modification when the causative food/s is/are successfully identified and eliminated.94 Three main dietary strategies have been employed—elemental formulas, empiric elimination diets of varying breadth, and allergy testing–guided food elimination—each representing a different trade-off between efficacy, dietary burden, and diagnostic precision (Table 2).95 Table 2Clinical Efficacy and Practical Considerations of Dietary Strategies for Inducing Remission in Eosinophilic EsophagitisDiet TherapyHistologic Efficacy in Children(<15 eos/hpf)Histologic Efficacy in Adults(<15 eos/hpf)Key Clinical and Practical ConsiderationsElemental Diet~90–95%71–94.5%Lacks antigenic capacity; highest overall efficacy. Severely limited by poor palatability, high cost, and risk of weight loss. Often requires a nasogastric tube in infants and significantly impairs health-related quality of lifeAllergy Testing-Directed Food Restriction~45.7–53%~26.4–34%Consistently low efficacy due to the non-IgE-mediated nature of EoE. Poor accuracy, low reproducibility, and sub-optimal negative predictive values (NPV) for skin prick tests (SPT), atopy patch tests (APT), and serum food panels. No longer recommended by clinical practice guidelines.Six-Food Elimination Diet (SFED)~60–68%Variable: 40–74%Historically the most extensively validated empirical diet, targeting milk, wheat, egg, soy/legumes, nuts, and seafood. High logistical burden due to broad social restrictions and the requirement for multiple sequential endoscopies (~5.6 per patient) to identify specific triggers during reintroduction. Adjuvant amino acid formula supplements can optimize nutritional status and improve histological outcomes.Four-Food Elimination Diet (FFED)54.7–64%~38–54%Pragmatic first-line alternative that selectively excludes cow’s milk, wheat, egg, and soy/legumes. Offers a significantly lower dietary restriction burden compared to SFED while maintaining robust clinical equivalence in randomized multi-site trials.Two-Food Elimination Diet (TFED)~40–43%~43%Core component of the progressive “Step-Up” protocol (2-4-6 approach). Selectively targets the two most ubiquitous food triggers: cow’s milk and wheat/gluten. Dramatically reduces the baseline number of endoscopies, cuts dietary expenses, and maximizes early patient compliance.One-Food Elimination Diet (1FED / Milk Avoidance)~46.4–55%~34%Currently considered the preferred first-line dietary strategy, particularly in pediatric cohorts. Focuses exclusively on strict dairy avoidance, requiring only a single follow-up endoscopy. Cross-reactivity mandates restriction of cow, sheep, and goat milk. Emergent evidence suggests potential tolerance to thermally modified (sterilized/baked) milk proteins or A2 beta-casein variations in specific patient subsets Clinical Efficacy and Practical Considerations of Dietary Strategies for Inducing Remission in Eosinophilic Esophagitis Across all dietary approaches, meta-analytic data consistently report an overall histological remission rate of approximately 60%,15 a figure that conceals considerable heterogeneity among individual strategies. Elemental diets achieve the highest efficacy, approaching 95%, by removing all intact proteins from the diet;95 however, their extreme restrictiveness limits real-world applicability.96 At the other end of the spectrum, allergy testing–guided diets yield the lowest response rates, reflecting the fundamentally non-IgE-mediated nature of the disease.44,97 Empiric elimination diets of varying breadth occupy the middle ground, with remission rates scaling broadly with the number of excluded food groups.15 Two consistent findings emerge from this body of evidence. First, efficacy tends to be higher in children than in adults across most dietary approaches,97 possibly reflecting differences in disease phenotype, dietary compliance, or the relative contribution of individual food triggers across age groups. Second, a ceiling effect appears to exist: expanding dietary restrictions beyond four to six food groups yields diminishing returns while substantially increasing patient burden.96,98 Elemental Diet An elemental diet consists of exclusive feeding with an amino acid-based formula, while avoiding all kinds of table foods. The first use of an elemental diet in the EoE literature was published in 1995,99 just after the characterization of the disease, in a series of pediatric patients with esophageal eosinophilia, and symptoms attributed to gastroesophageal reflux and refractory to other therapies. After an 8-week period, the esophageal histology normalized and symptoms resolved, but both recurred rapidly upon return to a normal diet, thus initially demonstrating EoE as a particular form of food allergy, and providing the first evidence of efficacy for any therapy. Elemental formulas use free amino acids as a nitrogen source, and also contain, fats, sugars, vitamins, and nutrients in readily assimilated forms.100 They effectively eliminate all potential dietary antigens and have consistently demonstrated the highest efficacy among dietary therapies, with an overall effectiveness of 94.5% (95% CI, 92.3–96.4%) in the latest meta-analysis, without statistical differences among age groups.15 Despite this superiority, elemental diets face substantial practical barriers, including poor palatability —in children a nasogastric tube may be needed to ensure proper intake of calories— resulting in decreased levels of adherence, impaired psychosocial functioning and quality of life, and weight loss.96 In fact, more than one-third of adults with active EoE (38%) failed to adhere to the diet over a 4 week period.101 Elemental diets therefore, are exclusively reserved for infants or those patients with severe, refractory EoE without other treatment options.2 Allergy Testing-Directed Food Elimination Diet Following the recognition of EoE as a new form of food allergy, research shifted toward trying to identify patient-specific dietary triggers. The aim was to implement targeted elimination diets, while avoiding unnecessary dietary restrictions. Different studies used different modalities of allergy testing, including skin prick test (SPT), atopy patch testing (APT), and serum food-specific IgE levels, or combinations thereof. Elimination diets guided by any allergy testing results demonstrated an overall efficacy in achieving histological remission of 39.5% (95% CI, 30.3–49.2%). However, there was high inconsistency between studies (I2 = 78.8%), indicating limited reproducibility. Summary estimates for effectiveness did not vary when different allergy tests or combinations of tests were compared. Notably, effectiveness was significantly lower in adults compared to children (26.4% vs 45.7%, respectively). Furthermore, the positive predictive values of the different food tests were shown to be consistently low in different studies.102,103 This led the majority of patients to restrict a high number of foods from their diets104 —despite several having no causal relationship with EoE— and therefore, to fail in the attempt to reduce the level of food restriction. Given the inaccuracy of available allergy testing and lower response rates compared to empiric elimination diets, allergy test-based diets are not currently recommended, and serum IgE or IgG food panels should not be ordered for EoE.2 This likely reflects the T-cell-mediated nature of EoE rather than classical IgE-mediated hypersensitivity. Empiric Elimination Diets The rationale for empiric elimination diets lies in removing the foods most frequently associated with food allergies without prior testing, since conventional allergy tests lack the sensitivity and specificity required to identify the causal triggers in most cases. The so-called empiric six-food elimination diet (SFED)—which excludes milk, wheat, eggs, soy/legumes, nuts, and fish/seafood—remains the most extensively validated dietary intervention in EoE. Initially introduced in pediatric cohorts in 2006,105 and subsequently adopted for adult populations,106,107 the SFED achieved robust histological remission rates of 63.9% to 68%,15 highly consistent across all age groups. Once histological remission with endoscopy and biopsies had been documented, food reintroduction allowed the identification of specific food trigger/s in each patient by documenting eosinophilic inflammation recurrence.106–108 Upon systematic food reintroduction, cow’s milk emerged as the most prevalent trigger, followed closely by wheat and eggs. More than one food trigger was identified in a proportion of patients. Despite its high efficacy, the clinical utility of the SFED is severely limited by its highly restrictive nature and the substantial logistical burden of the reintroduction protocol.109 The process typically requires sequential, single-group food reintroductions, followed by an endoscopy every six weeks, making it exceptionally time-consuming and onerous for patients.110 To mitigate these challenges, less restrictive empiric protocols have been developed. The four-food elimination diet (FFED)—which targets milk, wheat, eggs, and legumes/soy—offers a more pragmatic alternative.111,112 A meta-analysis of seven prospective cohorts, comprising 329 patients, demonstrated a pooled histological remission rate of 54.7% (95% CI, 45.7–63.6%; I2 = 57.7%).15 Dietary restrictions can be further streamlined via the two-food elimination diet (2FED),113 which selectively excludes milk and wheat, the two most ubiquitous triggers. The 2FED induces histological remission in approximately 43% of patients, with no differences across ages. The Rise of the One-Food Elimination Diet The overwhelming predominance of cow’s milk as the primary driver of EoE provided the rationale for evaluating a single-food elimination diet (1FED) focused exclusively on dairy avoidance. First systematically assessed in a pediatric cohort by Wechsler et al, the 1FED demonstrated that eliminating all cow’s milk protein-containing foods successfully achieved histological remission in over half of the evaluated patients, alongside concurrent endoscopic and symptomatic improvements.114 This efficacy was subsequently confirmed in a meta-analysis of seven studies (n = 224, including 145 children), yielding a pooled histological remission rate of 46.4% (95% CI, 40–52.9%; I2 = 49.8%),15 broadly comparable to the rates achieved with the more restrictive FFED. The comparative effectiveness of the 1FED versus the FFED was definitively evaluated in a landmark, multi-site randomized trial conducted by Kliewer et al across 10 US centers.115 Sixty-three pediatric patients with active, symptomatic EoE were randomized to either a 1FED or a 4FED (milk, egg, wheat, soy) for 12 weeks. The primary endpoint—symptom reduction measured by the Pediatric EoE Symptom Score (PEESS)—revealed equivalent efficacy. Both arms exhibited similar histological remission rates (41–44%) and comparable improvements in endoscopic, transcriptomic, and quality-of-life parameters. Crucially, the dropout rate was substantially higher in the 4FED arm (32% vs 11%), highlighting the real-world tolerability and adherence advantages of less restrictive dietary strategies. Collectively, these data support the 1FED as a highly viable, clinically meaningful first-line therapy, particularly in children. The efficacy of different dietary therapies is summarized in Table 2. Optimizing Endoscopic Efficiency: The Step-Up Approach To overcome the high attrition rates and the excessive endoscopic burden associated with traditional top-down elimination diets, a landmark 2018 multicenter Spanish study introduced a progressive step-up strategy.113 This protocol initiates therapy with a less restrictive 2FED (dairy and wheat), which successfully induced remission in 43% of the combined pediatric and adult cohort. Non-responders progressively advanced to a 4FED and, if necessary, to a 6FED, yielding final histological response rates equivalent to historical top-down data. Compared with the latter, this step-up approach resulted in early identification of a majority of responders to an empiric diet with few food triggers, and proved significantly more efficient in reducing total endoscopic procedures and the overall time required to identify specific food triggers by 20%.113 Immunopathogenesis of Milk-Induced EoE and the Impact of Industrial Processing Animal milk is the most frequently implicated antigen in EoE, but the precise mechanisms underlying milk-induced esophageal inflammation remain complex. Both IgE-mediated and, predominantly, non-IgE-mediated Type 2 helper T-cell (Th2) immune pathways seem to be involved,116 with bovine proteins, such as casein and whey, acting as potent antigens that induce a Th2-skewed immune response in genetically predisposed individuals.117 The widespread adoption of industrial milk processing techniques, particularly ultra-high temperature (UHT) sterilization and high-pressure homogenization, has fundamentally altered the physicochemical properties of cow’s milk, with profound implications for its immunogenicity.118 In its native state, milk fat globules are stabilized by a specialized phospholipid and protein membrane. Homogenization disrupts this structure, fragmenting fat globules from the micrometer to the nanometer scale. Deprived of their native membrane, casein micelles and whey proteins readily adsorb onto these newly formed lipid surfaces,119 generating novel lipid-protein nanostructures completely absent in raw milk.120 Concurrently, UHT treatment induces thermal protein denaturation, potentially unmasking cryptic epitopes or creating neoantigens.121,122 These structurally altered nanoparticles may possess distinct biological properties that accelerate EoE pathogenesis. Their reduced physical dimensions may facilitate paracellular penetration across a compromised esophageal epithelial barrier, while their dense protein coating may enhance uptake by local antigen-presenting cells. This adjuvant-like activity has been proposed to drive a distinct, non-classical allergic response, characterized by markedly elevated titers of IgG4 antibodies directed against major bovine proteins, specifically α-lactalbumin (Bos d 4), β-lactoglobulin (Bos d 5), and casein (Bos d 8).118,123 Unlike classical IgE-mediated food allergies, this IgG4-dominated pathway may lead to the local deposition of immune complexes within the esophageal lamina propria, further perpetuating chronic inflammation.42 However, it must be critically noted that this model remains largely hypothetical. Direct causal evidence linking processed milk consumption to IgG4-driven esophageal inflammation in humans is still limited.124 Furthermore, the relative contribution of processing-induced structural changes versus host genetic susceptibility and intrinsic epithelial barrier dysfunction has yet to be formally established. The clinical relevance of milk processing in EoE pathogenesis is further supported by evidence suggesting that thermal modification of milk proteins may reduce their capacity to trigger esophageal inflammation in a subset of patients.125,126 Heat treatment at high temperatures induces irreversible protein denaturation, altering the three-dimensional structure of major conformational epitopes and potentially reducing their recognition by the local immune system127 —as already documented in the improved tolerance to baked milk in patients with classical IgE-mediated cow’s milk allergy.128 In this context, a prospective study provided direct evidence that sterilized cow’s milk—processed through prolonged boiling rather than industrial UHT pasteurization—was tolerated long term by two thirds of adult patients with documented milk-triggered EoE.125 From a clinical standpoint, sterilized milk may represent a viable, less restrictive dietary option for selected patients, able to improve quality of life and nutritional adequacy in individuals otherwise facing long-term, strict dairy elimination. Finally, not only changes in milk processing, but also selection of new cattle varieties might have affected the emergence of milk-induced EoE, as recently proposed in a Swiss study:129 Most patients with milk-triggered EoE were able to consume A2 beta casein milk with no recurrence of eosinophilic inflammation.129 Th2 cytokines were released to the supernatant from esophageal biopsies of these patients when exposed to standard milk, but not when incubated with A2 beta casein milk. Beta-casein makes up about 30% of the whole protein in cow’s milk. It comes in two primary genetic variants: A1 and A2, which only differentiate in a polymorphism at the 67 amino acid chain.130 Historically, all cows produced only the A2 protein, but a genetic mutation occurred in some European breeds, creating the A1 protein. Today, most standard commercial dairy cows produce a mix of A1 and A2. When A1 protein is digested, it releases beta-casomorphin-7 (βCM-7), a peptide with theoretical potential advantages to gastrointestinal health,131 but able to trigger inflammation.132 Studies have now opened a debate on the potentially harmful effects of A1 β-casein to adult and infant health, which should be clarified in future studies.133 Future Directions and Unmet Needs Despite significant progress in understanding eosinophilic esophagitis (EoE), several clinical and scientific challenges remain unresolved. Future research must address these gaps to improve patient care, refine diagnostic tools, and optimize long-term therapeutic strategies. Non-Invasive Biomarkers The greatest unmet need in EoE diagnosis and management is the discovery of reliable, non-invasive biomarkers. Currently, diagnosing EoE and monitoring disease activity and response to treatment—especially during dietary reintroduction—requires repeated endoscopies with biopsies.2 The acceptance of this invasive approach requires sedation, but is still burdensome for patients, particularly children. In addition, endoscopy represents the highest health cost for EoE in the first year after diagnosis.134 Less invasive sampling tools, such as the cytosponge135 and the esophageal string test,136 able to capture esophageal cells and secretions, respectively, have shown promising results in EoE monitoring, but are still under investigation. Saliva,137 blood138 or serum-derived biomarkers139 should be better accepted, but their ability to accurately reflect esophageal eosinophilia and tissue remodeling still need to be established.140 Predicting Risk in Oral Immunotherapy As food OIT becomes more common for IgE-mediated allergies, predicting which patients will develop OIT-induced EoE is critical. Availability of noninvasive biomarkers should allow screening for subclinical EoE before starting OIT. Symptom tools should be mandatory to help identify those patients at risk of developing OIT-induced EoE. Research must concentrate on identifying predictive risk factors for developing EoE, focused on baseline esophageal tissue characteristics, specific immune profiles or even genetic variations that put patients at risk. Understanding these risk factors will allow clinicians to screen patients before starting OIT and intervene early if symptoms appear. Patient Phenotyping and Precision Medicine in EoE Adopting a personalized strategy would represent the optimal approach for EoE management. Consequently, patient phenotyping has emerged as a fundamental clinical necessity for accurately predicting disease progression, treatment response, and long-term outcomes. Atopic comorbidity in EoE ranges from non-atopic patients to those with severe multi-atopic burdens. Characterizing this “allergic phenotype”—strongly linked to rhinitis, asthma, and dermatitis—is important,141 as it may potentially predict complex disease courses, dietary compliance, and distinct responses to targeted therapies. In this sense, groundbreaking research has enabled the characterization of EoE into distinct phenotypes—termed “endotypes” by authors—based on clinical features, endoscopic findings, therapeutic responses, and genetic or molecular markers in esophageal biopsies.142 This classification is poised to shift the current paradigm of EoE from a single entity to a spectrum of distinct patient cohorts. These would include a mild phenotype (characterized by non-severe symptoms and purely inflammatory endoscopic features), a severe/aggressive phenotype (defined by recurrent food impaction, a narrow-caliber esophagus, or stricturing disease prone to immediate relapse upon treatment discontinuation, coupled with high levels of gene expression), and an intermediate phenotype, where strictures and symptoms would steadily progress in the absence of effective therapy. To date, these EoE endotypes have not been definitively linked to specific atopic profiles.141 Future research must focus on identifying molecular assays capable of defining clinical, endoscopic, and histopathological phenotypes. Understanding how targeted therapies can alter the natural history of phenotypes will allow clinicians to tailor therapeutic approaches from the outset, distinguishing patients suited for minimal dietary interventions from those requiring aggressive pharmacological strategies or extensive elimination diets. Personalized Dietary Interventions Although empirical approaches represent the most effective approach for the dietary treatment of EoE, their application is far from optimal, and a proportion of treated patients will not be able to follow this therapy long-term.143 Moving to a personalized strategy would be an optimal approach. For this, future studies should focus on identifying specific dietary triggers using advanced molecular testing, rather than trial-and-error elimination. Additionally, research needs to determine the long-term safety and nutritional impact of less restrictive diets over a number of years. Expanding the Biologics Pipeline The therapeutic landscape of EoE has entered a new era with the approval of dupilumab, a monoclonal antibody targeting the IL-4/IL-13 receptor.144 However, there is still a need to expand and refine the biologics pipeline by targeting alarmins (such as TSLP with tezepelumab and sulrikitug),145 or fibrous remodeling pathways. With the advantage of managing several atopic concomitance with a single drug, key questions remain regarding selection of best candidates, cost-effectiveness, optimal positioning within current treatment protocols, and their ability to modify the natural history of EoE. The Role of the Esophageal Microbiota Emerging evidence suggests that the esophageal microbiota may play a significant regulatory role in the maintenance of homeostasis in the esophageal mucosa,146,147 and there are measurable changes in the microbiome composition in different esophageal diseases,31 including EoE.148 Active EoE is often associated with local dysbiosis, characterized by an increased abundance of pro-inflammatory genera, like Prevotella and Haemophilus, and a decrease in protective Lactobacillales.149 This microbial imbalance may impair the epithelial barrier, activate inflammatory responses150 and increase susceptibility to food antigens. Standard treatments, including dietary elimination and corticosteroids, have been shown to alter this microbial composition.148 Future research must determine whether these microbial changes are a cause or a consequence of esophageal inflammation. Investigating the therapeutic potential of targeted probiotics or prebiotics to restore immune balance represents a promising and innovative frontier in EoE care. Conclusion EoE represents a complex, tissue-specific manifestation of type 2 allergy that challenges conventional paradigms of food allergy and immune tolerance. As highlighted by its de novo development during oral immunotherapy, systemic desensitization and robust plasma IgG4 production do not equate to local esophageal tolerance, where the persistence of pathogenic Th2 cells and mucosal IgG4 immune complexes perpetuate inflammation. Given the suboptimal diagnostic utility of traditional allergy testing, empiric dietary elimination remains a cornerstone of first-line therapy, further optimized by streamlined protocols and an evolving understanding of how industrial food processing alters allergen immunogenicity. Ultimately, bridging the gap between systemic immunity and the unique microenvironment of the refractory esophagus will be critical in advancing from trial-and-error dietary interventions towards non-invasive biomarkers and precision therapeutic targets in EoE management. Acknowledgments We are grateful to Melanie Radcliff for English language revision. Funding Statement The authors declare that no funding was received for this article. Abbreviations 1FED, one-food elimination diet; 2FED, two-food elimination diet; 4FED, four-food elimination diet; 6FED, six-food elimination diet; APT, atopy patch testing; CAPN14, calpain-14; CI, confidence interval; DCs, dendritic cells; EoE, eosinophilic esophagitis; eos/hpf, eosinophils per high-power field; FA, food allergy; FARE, Food Allergy Research & Education; FFED, four-food elimination diet; GATA3, GATA binding protein 3; HRQoL, health-related quality of life; IgE, immunoglobulin E; IgG4, immunoglobulin G4; IL, interleukin; ILC-2, innate lymphoid cells type 2; NPV, negative predictive value; OIT, oral immunotherapy; OR, odds ratio; PEESS, Pediatric EoE Symptom Score; peTh2, pathogenic type 2 helper T lymphocytes; PPIs, proton pump inhibitors; SFED, six-food elimination diet; sIgE, allergen-specific immunoglobulin E; SPINK7, serine peptidase inhibitor Kazal type 7; SPT, skin prick testing; TFED, two-food elimination diet; Th2, T helper type 2; T-reg, T-regulatory cells; TSLP, thymic stromal lymphopoietin; UHT, ultra-high temperature; USA, United States of America; βCM-7, beta-casomorphin-7. Data Sharing Statement Data sharing is not applicable to this article as no new data were created or analyzed in this study. Author Contributions M.P.: Conceptualization, Investigation, Writing – original draft. I.M.R.G.: Investigation, Writing – original draft. E.G.N.: Investigation, Writing – original draft. A.J.L.: Conceptualization, Supervision, Writing – original draft, Writing – review & editing, Project administration. All authors took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work. Disclosure Alfredo Lucendo reports consulting fees from Dr. Falk Pharma, AstraZeneca, Sanofi/Regeneron; Honoraria from Sanofi/Regeneron and travel support from Dr. Falk Pharma. The authors report no other conflicts of interest. References Associated Data Data Availability Statement Data sharing is not applicable to this article as no new data were created or analyzed in this study.